HC Wainwright & Co. Reiterates Buy on Aurinia Pharmaceuticals, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) and maintained a price target of $15.
September 22, 2023 | 10:20 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aurinia Pharmaceuticals has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $15.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Aurinia Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100